Moderna Inc (MRNA) Stock Price, Trades & News

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	3.99
Equity-to-Asset	0.62
Debt-to-Equity	0.19
Debt-to-EBITDA	-0.46
Piotroski F-Score	1/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.17	Distress Grey Safe
Beneish M-Score	-3.83	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-52.2
	3-Year Book Growth Rate	-23.8
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	25.27
	Future 3-5Y Total Revenue Growth Rate Estimate	17.08

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	57.85
	9-Day RSI	62.79
	14-Day RSI	64.13
	3-1 Month Momentum %	16.17
	6-1 Month Momentum %	2.33
	12-1 Month Momentum %	127.56

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.29
	Quick Ratio	2.18
	Cash Ratio	2.03
	Days Inventory	49.22
	Days Sales Outstanding	44.72
	Days Payable	46.49

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-0.8
	Shareholder Yield %	-0.58

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	22.76
	Operating Margin %	-150.23
	Net Margin %	-142.58
	EBITDA Margin %	-126.88
	FCF Margin %	-56.29
	OCF Margin %	-48.55
	ROE %	-37.92
	ROA %	-26.73
	ROIC %	-49.53
	3-Year ROIIC %	143.1
	ROC (Joel Greenblatt) %	-106.49
	ROCE %	-31.22
	Years of Profitability over Past 10-Year	2
	Moat Score	7
	Tariff Resilience Score	4

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	Shiller PE Ratio	112.27
	PS Ratio	24.88
	PB Ratio	8.28
	Price-to-Tangible-Book	8.48
	EV-to-EBIT	-17.14
	EV-to-Forward-EBIT	-14.64
	EV-to-EBITDA	-18.61
	EV-to-Forward-EBITDA	-15.65
	EV-to-Revenue	23.61
	EV-to-Forward-Revenue	24.98
	EV-to-FCF	-41.94
	Price-to-GF-Value	5.81
	Price-to-Projected-FCF	2.97
	Price-to-Net-Current-Asset-Value	34.65
	Price-to-Net-Cash	59.72
	Earnings Yield (Greenblatt) %	-5.83
	FCF Yield %	-2.22

Financials (Next Earnings Date:2026-11-06 Est.)

Annual Quarterly TTM

MRNA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with NAS:MRNA

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Moderna Inc Executives

Details

GF Value™: $24.15

MRNA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with MRNA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)	2,210
	EPS (TTM) ($)	-7.99
	Beta	0.3223
	3-Year Sharpe Ratio	-0.15
	3-Year Sortino Ratio	-0.24
	Volatility %	164.13
	14-Day RSI	64.13
	14-Day ATR ($)	14.335366
	20-Day SMA ($)	99.30125
	12-1 Month Momentum %	127.56
	52-Week Range ($)	22.28 - 176.66
	Shares Outstanding (Mil)	399.24

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	1
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Moderna Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Moderna Inc Stock Events

Financials Calendars

Event	Date	Price ($)
Annual report for 2026	2027-02-19	In 171 days
Fourth quarter earnings conference call for 2026	2027-02-12 08:00	In 165 days
Fourth quarter earnings results for 2026	2027-02-12	In 164 days
Third quarter earnings conference call for 2026	2026-11-06 08:00	In 67 days
Third quarter earnings results for 2026	2026-11-06	In 66 days
Second quarter earnings conference call for 2026	2026-07-31 08:00	57.92 (+3.49%)
Second quarter earnings results for 2026	2026-07-31	57.92 (+3.49%)
Moderna Science Day	2026-06-25 09:00	60.42 (-1.23%)
Guidance call for 2026	2026-06-09 15:20	47.60 (-1.29%)
Bernstein\'s 42nd Annual Strategic Decisions Conference	2026-05-28 10:00	47.61 (+1.25%)

Show

Entries

Moderna Inc Frequently Asked Questions

What is Moderna Inc(MRNA)'s stock price today?

The current price of MRNA is $140.34. The 52 week high of MRNA is $176.66 and 52 week low is $22.28.

When is next earnings date of Moderna Inc(MRNA)?

The next earnings date of Moderna Inc(MRNA) is 2026-11-06 Est..

Does Moderna Inc(MRNA) pay dividends? If so, how much?

Moderna Inc(MRNA) does not pay dividend.

Guru Commentaries on NAS:MRNA

No fund manager commentary yet.

Browse all fund letters →

Press Release

	Subject	Date
	Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates	2026-05-01
	Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate	2026-04-21
	Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting	2026-04-21
	Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19	2026-04-21
	Moderna to Present at Upcoming Conferences in May 2026	2026-04-21
	Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026	2026-04-15
	Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026	2026-04-06
	Moderna Resolves Global Patent Litigation with Arbutus/Genevant	2026-03-03
	Moderna to Present at Upcoming Conferences in March 2026	2026-02-19
	Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission	2026-02-18

10/Page

Articles on Moderna Inc

MRNA

MRNA Looks 476.4% Overvalued on GF Value™

10 hours ago

VISN

Market Today: Fed Rate Hike Signals, Meta Settlement, Nvidia Earnings

3 days ago

MRNA

MRNA Looks 490.4% Overvalued on GF Value™ Amid Convertible Note Offering

4 days ago

MRNA

MRNA Looks 480.9% Overvalued on GF Value™

4 days ago

MRNA

MRNA Looks 518.9% Overvalued on GF Value™

5 days ago

Headlines

Aug 28, 2026

Arcturus, Moderna fall after BioNTech's cancer vaccine setback

Seeking Alpha • 1:08pm

BioNTech falls as it ends mid-stage trial of mRNA colorectal cancer vaccine

Seeking Alpha • 10:39am

4 stocks to watch on Friday: MRNA, GILD, JBLU, and LLY

Seeking Alpha • 8:02am

Moderna prices upsized $2.6B offering of convertible senior notes

Seeking Alpha • 6:09am

Aug 27, 2026

HHS advisors to discuss boosting funding for autism care

Seeking Alpha • 10:02am

Aug 26, 2026

Wall Street edges lower after inflation data and ahead of Nvidia earnings

Seeking Alpha • 9:35am

Aug 25, 2026

Wall Street climbs ahead of Nvidia earnings and key inflation data

Seeking Alpha • 9:16am

Aug 24, 2026

Personalis falls amid a downgrade as a competitive bid appears unlikely

Seeking Alpha • 12:14pm

Biotech Breakout: What's in focus after Moderna's cancer win?

Seeking Alpha • 12:12pm

Aug 21, 2026

HHS seeking public input on vaccine recommendation categories

Seeking Alpha • 1:21pm

Aug 20, 2026

4 stocks to watch on Thursday: BABA, WMT, MRNA, SHOP

Seeking Alpha • 7:51am

Moderna breakthrough: The options lottery tickets that paid out

Seeking Alpha • 3:58am

Trump’s Moderna bet gets a double dose

Seeking Alpha • 3:50am

Moderna nearly triples in record S&P 500 move, but analyst sees more volatility ahead

Seeking Alpha • 3:17am

Aug 19, 2026

Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck

Seeking Alpha • 1:38pm

New CDC director says vaccines are 'safe and effective'

Seeking Alpha • 1:38pm

BioNTech’s rally on Moderna trial win likely to fade, Leerink says

Seeking Alpha • 11:08am

Wall Street trades mixed and yields slide after the latest Treasury Department announcement

Seeking Alpha • 9:13am

Moderna surges on trial win for cancer shot; William Blair upgrades

Seeking Alpha • 9:09am

Healthcare ETFs rally as Moderna nearly doubles on melanoma win

Seeking Alpha • 8:13am

At a glance: stocks gapping up premarket

Seeking Alpha • 7:12am

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.